KPV Peptide: Evidence, Mechanism, Dosing & Legal Status

KPV (Lysine-Proline-Valine; Lys-Pro-Val) is the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), marketed in grey-market and compounding channels as an anti-inflammatory agent for gut, skin and wound applications.1 Its mechanistic story is unusually clean; its proof in humans is nonexistent. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. KPV is not an FDA-approved drug; it has never been tested in a human clinical trial and is sold as a "research chemical not for human use." Dosing figures are reported strictly as seen in the preclinical literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is KPV and how does it work?

KPV is the C-terminal tripeptide — lysine-proline-valine, residues 11-13 — of alpha-MSH, an endogenous 13-residue cleavage product of proopiomelanocortin (POMC). Decades of work established that much of alpha-MSH's anti-inflammatory activity is concentrated in this minimal sequence, which lacks the melanocortin core responsible for receptor-driven pigmentation, so KPV does not cause tanning or the appetite and metabolic effects associated with full-length alpha-MSH.2

The core mechanism — all of it preclinical — is intracellular and substantially melanocortin-receptor-independent. The landmark mechanistic study showed that, at nanomolar concentrations, KPV is transported into cells by the PepT1 di/tripeptide transporter (uptake blocked by the competing substrate Gly-Leu, establishing PepT1 dependence), inhibits NF-kappaB activation by blocking IkappaB-alpha phosphorylation and degradation, suppresses the ERK1/2, JNK and p38 MAP-kinase pathways, and thereby reduces pro-inflammatory cytokine and chemokine output such as IL-8 in human intestinal epithelial cells and Jurkat T cells.1 This route is therapeutically convenient because PepT1 is normally low or absent in healthy colon but is up-regulated specifically in inflamed colonic epithelium and macrophages during inflammatory bowel disease — so the transporter that carries KPV is enriched exactly where inflammation is.6 Independently of immune modulation, KPV also exerts direct antimicrobial activity against Staphylococcus aureus and Candida albicans down to picomolar concentrations, apparently by raising cAMP within the pathogen, without impairing host neutrophil killing.2 Formal human pharmacokinetics are unpublished; as a small, relatively stable tripeptide KPV is amenable to oral delivery via intestinal PepT1, but human bioavailability, half-life and topical absorption remain unknown.3

What is the evidence by indication?

Across every indication, the evidence is preclinical — animal models and/or in-vitro cell culture. There are no human randomized controlled trials, no cohort studies, and no registered human trials for KPV as of June 2026. Human "uses" are mechanistic extrapolation, not demonstrated clinical efficacy. The overall grade is C.

The intestinal-inflammation evidence is the strongest and most extrapolated. In the foundational study, oral KPV (~100 micromolar in drinking water) attenuated both DSS- and TNBS-induced colitis in mice: reduced body-weight loss, lower colonic myeloperoxidase activity, improved histology, and decreased mucosal mRNA for IL-6, IL-12, IFN-gamma, IL-1beta and TNF-alpha, with in-vitro nanomolar KPV blocking NF-kappaB and IL-8.1 An independent group corroborated anti-inflammatory benefit in two murine IBD models.5 Targeted oral nanoparticle delivery at 16 micrograms/kg/day normalized TNF-alpha, spleen weight, colon length, MPO and histology toward healthy controls in DSS colitis, though sample sizes were small.3 In an AOM/DSS model, KPV also reduced colitis-associated tumor number, size and burden, an effect abolished in PepT1-knockout mice — hypothesis-generating mouse-only data, not a basis for any human anticancer claim.4 The full Federal Register notice for the upcoming compounding review can be read at federalregister.gov, which lists KPV among the nominated substances.8

What doses appear in the literature?

Reported strictly as information, not a protocol. No validated, safe or effective human dose exists because KPV has never been tested in humans.1 In mouse colitis, roughly 100 micromolar KPV in drinking water or about 16 micrograms/kg/day by oral gavage for around five days produced anti-inflammatory effects; oral is the route best supported by IBD data because inflamed colon over-expresses PepT1.1 Anti-inflammatory effects appear at nanomolar concentrations in vitro and antimicrobial effects down to picomolar.2 Experimental targeted-delivery systems — hyaluronic-acid-functionalized PLGA nanoparticles in a chitosan/alginate hydrogel for colon-specific release — were markedly more potent than free KPV in models.3 Grey-market and clinic material describe oral capsules in a roughly 200-500 microgram/day range and topical skin preparations, but these figures are unsupported by any human trial and reflect compounding anecdote, reported here only to characterize the unregulated landscape, not as guidance.12

How safe is KPV?

Human safety is unknown. With no human trials, there is no characterized human adverse-event profile, no established maximum tolerated dose, and no long-term safety data; any "well-tolerated" framing applies only to animals and cells.1 Across roughly two decades of alpha-MSH and KPV animal and in-vitro work, no prominent toxicity has been reported, and unlike alpha-MSH, KPV does not cause pigmentation or appetite changes because it does not activate melanocortin receptors — but absence of reported harm in animals is not evidence of human safety.2 Theoretical risks include cell-proliferation effects warranting caution in active or undiagnosed malignancy (though KPV reduced tumor burden in the colitis-cancer model rather than promoting it) and broad immune modulation that could blunt desirable immune responses.4 In practice the dominant and most concrete hazard is product quality: grey-market peptides carry documented mislabeling and contamination, which is a real and arguably the dominant practical hazard for any human exposure. Pregnancy, lactation and pediatric use are precautionary contraindications with no data.9

What is the FDA and WADA status in 2026?

KPV is not an FDA-approved drug for any indication and has no USP/NF monograph.7 The regulatory timeline is precise: on April 16, 2026 the FDA published a Federal Register notice (Doc. 2026-07361, docket FDA-2025-N-6895) announcing a Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 to consider whether several peptides — including KPV, alongside BPC-157, TB-500 and MOTS-c — should be added to the 503A Bulk Drug Substances List, with KPV's nomination citing wound healing and inflammatory conditions.8 Separately, twelve peptides were removed from the restricted Category 2 list in April 2026 after nominations were withdrawn — an easing of prior restriction, not an approval.11 PCAC votes are advisory, with final rulemaking typically issued 6-18 months later; even if added to 503A, KPV would remain a compounded prescription preparation, not an FDA-approved or OTC drug.10 KPV is not a DEA-controlled substance.

For athletes the picture is unfavorable. KPV is not explicitly named on the WADA Prohibited List, but as a pharmacological substance with no current approval by any government health authority for human therapeutic use, it falls under category S0 (non-approved substances) and is therefore prohibited at all times in tested sport; "research use only" labeling confers no protection.9 Any WADA-tested athlete or military service member should treat KPV as banned.9

Bottom line. KPV pairs a coherent, replicated animal and in-vitro anti-inflammatory mechanism with a near-total absence of human proof. The biology is appealing, but the gap between promise and proof is the headline — graded C, legally unsettled, and best treated as banned in sport. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.